{"filing":{"accession_number":"0001575872-26-000547","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-01","primary_document":"rdy0933_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000547/rdy0933_6k.htm"},"events":[{"id":22994,"run_id":20815,"accession_number":"0001575872-26-000547","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar, a significant regulatory milestone for the company's biosimilars portfolio. This is a material operational/strategic event—the approval of a complex biologic medicine in a major market (the U.S.) and the establishment of an exclusive commercialization partnership with Fresenius Kabi. While not a discrete M\u0026A transaction, earnings release, or other named event type, this regulatory approval and market entry represent a material advancement in the company's biosimilars business strategy and competitive position.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23125,"accession_number":"0001575872-26-000547","item_number":"EX-99.1","item_title":"rdy0933_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar, a significant regulatory milestone for the company's biosimilars portfolio. This is a material operational/strategic event—the approval of a complex biologic medicine in a major market (the U.S.) and the establishment of an exclusive commercialization partnership with Fresenius Kabi. While not a discrete M\u0026A transaction, earnings release, or other named event type, this regulatory approval and market entry represent a material advancement in the company's biosimilars business strategy and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:25:41.472724+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23125,"accession_number":"0001575872-26-000547","item_number":"EX-99.1","item_title":"rdy0933_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar, a significant regulatory milestone for the company's biosimilars portfolio. This is a material operational/strategic event—the approval of a complex biologic medicine in a major market (the U.S.) and the establishment of an exclusive commercialization partnership with Fresenius Kabi. While not a discrete M\u0026A transaction, earnings release, or other named event type, this regulatory approval and market entry represent a material advancement in the company's biosimilars business strategy and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:25:41.472724+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-08-03"}]}